Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.


Sci. STKE, 11 July 2000
Vol. 2000, Issue 40, p. tw1
[DOI: 10.1126/stke.2000.40.tw1]

EDITORS' CHOICE

Physiology HIV Protease Inhibitors Block Glut4 Activity

HIV protease inhibitor therapy, although beneficial to AIDS patients, often results in serious side effects with long-term administration. Frequently, patients develop insulin resistance that leads to type 2 diabetes. Murata et al. studied the effects of indinavir, an HIV protease inhibitor, on glucose transport and found that glucose uptake is severely reduced. Cells treated with indinavir did not exhibit defective insulin signaling, as measured by protein tyrosine phosphorylation, and translocation of the glucose transporters Glut1 and Glut4 to the plasma membrane was normal. However, Glut4- but not Glut1-mediated glucose transport across the cell membrane was diminished. Other HIV protease inhibitors also inhibited glucose uptake in 3T3-L1 cells; however, it was not demonstrated whether these inhibitors also selectively blocked the function of Glut4. These results suggest that the design of a new generation of protease inhibitors will have to account for undesirable glucose uptake inhibition.

Murata, H., Hruz, P.W., and Mueckler, M. (2000) The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J. Biol. Chem. 275: 20251-20254. [Abstract] [Full Text]

Citation: HIV Protease Inhibitors Block Glut4 Activity. Sci. STKE 2000, tw1 (2000).


To Advertise     Find Products


Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882